{"id":3526,"date":"2025-11-24T15:01:56","date_gmt":"2025-11-24T14:01:56","guid":{"rendered":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/?p=3526"},"modified":"2025-12-30T18:48:09","modified_gmt":"2025-12-30T17:48:09","slug":"1st-winter-school-of-pharmacovigilance-and-patient-safety-research-group","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/2025\/11\/24\/1st-winter-school-of-pharmacovigilance-and-patient-safety-research-group\/","title":{"rendered":"1st Winter School of Pharmacovigilance and Patient Safety Research Group Inter- and Multidisciplinary Chapters of Clinical Oncology, Patient Safety and Pharmacovigilance"},"content":{"rendered":"

INVITATION<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

\u00a0<\/p>\n

We kindly invite you to the scientific event organized by the Pharmacovigilance and Patient Safety Research Group, Department of Internal Medicine and Oncology, Oncology Unit, Semmelweis University and the Central and Eastern European Academy of Oncology:<\/p>\n

\u00a0<\/p>\n

1st Winter School of Pharmacovigilance and Patient Safety Research Group<\/em><\/strong><\/p>\n

\u00a0<\/em><\/strong><\/p>\n

Inter- and Multidisciplinary Chapters of Clinical Oncology, <\/em><\/strong><\/p>\n

Patient Safety and Pharmacovigilance<\/em><\/strong><\/p>\n

\u00a0<\/strong>training course & conference<\/p>\n

\u00a0<\/p>\n

Date: <\/strong>19th<\/sup> & 20th<\/sup> December, 2025<\/p>\n

Venue:<\/strong> Central and Eastern European Oncology Academy<\/p>\n

1125 Budapest, Diana u. 6\/c<\/p>\n

\u00a0<\/p>\n

The participants will receive Certificate of Attendance upon request.<\/strong><\/p>\n

 <\/p>\n

This will be a hybrid event, with the option to attend in person or participate online<\/a><\/u>.<\/p>\n

The official language of the conference is English. Participation is free of charge but requires registration.<\/p>\n

Please send your registration to:<\/p>\n

drugresearch.oncology@semmelweis.hu<\/a><\/p>\n

\u00a0<\/strong><\/p>\n

Budapest, 10th<\/sup> November, 2025.<\/p>\n

\u00a0<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0 Dr. M\u00e1t\u00e9 \u00c1d\u00e1m Bal\u00e1zs<\/strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Dr. Attila Marcell Sz\u00e1sz<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Prof. Dr. Magdolna Dank<\/strong><\/span><\/p>\n

Secretary of the Research Group\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Vice-President\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Head of the Research Group<\/span><\/p>\n

\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 CEEAO\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Director General<\/span><\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

PRELIMINARY PROGRAM*<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

1st Winter School of Pharmacovigilance and Patient Safety Research Group<\/em><\/strong><\/p>\n

\u00a0<\/em><\/strong><\/p>\n

Inter- and Multidisciplinary Chapters of Clinical Oncology, <\/em><\/strong><\/p>\n

Patient Safety and Pharmacovigilance*<\/em><\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Date: <\/strong>19th<\/sup> December 2025 (Friday)<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

Day 1<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

14:00 – 14:10<\/p>\n<\/td>\n

\n

 <\/p>\n

Opening Remarks<\/strong><\/p>\n

 <\/p>\n

Prof. Dr. Magdolna Dank<\/u><\/em><\/strong>, director general, National Institute of Oncology, Budapest, Hungary; Head of Pharmacovigilance and Patient Safety Research Group, Department of Internal Medicine and Oncology, Oncology Unit, Semmelweis University<\/em><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

14:10 \u2013 14:20<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Welcome Address<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Dr. M\u00e1t\u00e9 \u00c1d\u00e1m Bal\u00e1zs<\/u><\/em><\/strong>, secretary, Pharmacovigilance and Patient Safety Research Group, Oncology Unit, Department of Internal Medicine and Oncology, Semmelweis University, <\/em>Budapest, Hungary<\/em><\/p>\n

\u00a0<\/em><\/p>\n<\/td>\n<\/tr>\n

\n

14:20 \u2013 14:30<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Why can be a big advantage to choose scientific research work as medical student?<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Devarajulu Mariyappan<\/u><\/em><\/strong>, student research associate, <\/em>Pharmacovigilance and Patient Safety Research Group, Oncology Unit, Department of Internal Medicine and Oncology, Semmelweis University, <\/em>Budapest, Hungary <\/em><\/p>\n

\u00a0<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

14:30 – 15:00<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Scientific writing: how to get published<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Akhmedov Mobil I.<\/u><\/em><\/strong>, oncologist PhD, M.D. Senior Researcher at the Group of High-dose chemotherapy and Bone marrow Transplantation. Department of Drug Treatment of Tumors at the P. Hertsen Moscow Oncology Research Institute \u2013 Branch of the NMRRC <\/em><\/p>\n

\u00a0<\/em><\/p>\n<\/td>\n<\/tr>\n

\n

15:00 – 15:30<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Practical advice on preparing a presentation of a scientific report<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Shuvaev Vasily A.<\/u><\/em><\/strong>, hematologist Doctor of Medical Sciences Department of Hematology and Chemotherapy of the A. Tsyb Medical Radiological Research Centre – Branch of the NMRRC<\/em><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

15:30 – 16:00<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Simple steps to a strong and effective science presentation<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Sedova Maria V.<\/u><\/em><\/strong>, oncologist Phd, M.D. Daycare Hospital for the Drug Treatment of tumors at the P. Hertsen Moscow Oncology Research Institute \u2013 Branch of the NMRRC <\/em><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

16:00 – 16:30<\/strong><\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Coffee Break<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

16:30 \u2013 17:00<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

History of drug antitumor treatment<\/strong><\/p>\n

\u00a0<\/em><\/p>\n

Snegovoy Anton V.<\/u><\/em><\/strong>, oncologist. Doctor of Medical Sciences Deputy Director General of the NMRRC. Head of the Department of Drug Treatment of Tumors at the N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology \u2013 Branch of the NMRRC <\/em><\/p>\n

\u00a0<\/em><\/p>\n<\/td>\n<\/tr>\n

\n

17:00 – 17:30<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Conducting an Effective Scientific Literature Search<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

P\u00e9ter Szluka<\/u><\/em><\/strong>, director, Central Library, Semmelweis University, Budapest, Hungary<\/em><\/p>\n

\u00a0<\/em><\/p>\n<\/td>\n<\/tr>\n

\n

17:30 \u2013 18:00<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Maintenance therapy in oncology. Management of adverse events<\/strong><\/p>\n

during drug antitumor treatment<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Snegovoy Anton V.<\/u><\/em><\/strong>, oncologist. Doctor of Medical Sciences Deputy Director General of the NMRRC. Head of the Department of Drug Treatment of Tumors at the N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology \u2013 Branch of the NMRRC<\/em><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

18:00 \u2013 18:10<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Closing Remarks<\/strong><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

*The organizers reserve the right to change the program.<\/em><\/p>\n

\u00a0<\/p>\n

 <\/p>\n

\u00a0<\/strong><\/p>\n

PRELIMINARY PROGRAM*<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

1st Winter School of Pharmacovigilance and Patient Safety Research Group<\/em><\/strong><\/p>\n

\u00a0<\/em><\/strong><\/p>\n

Inter- and Multidisciplinary Chapters of Clinical Oncology, <\/em><\/strong><\/p>\n

Patient Safety and Pharmacovigilance*<\/em><\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Date: <\/strong>20th<\/sup> December 2025<\/p>\n

\u00a0<\/p>\n

Day 2<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

09:00 – 09:10<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Opening Remarks<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Dr. M\u00e1t\u00e9 \u00c1d\u00e1m Bal\u00e1zs<\/u><\/em><\/strong>, secretary, Pharmacovigilance and Patient Safety Research Group, Oncology Unit, Department of Internal Medicine and Oncology, Semmelweis University, <\/em>Budapest, Hungary<\/em><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

09:10 \u2013 09:40<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Pre-clinical animal studies – Basic research of new clinical compounds <\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Prof. Dr. Aleksandar Ra\u0161kovi\u0107<\/u><\/em><\/strong>, full professor, Head of the Department of Pharmacology, Toxicology and Clinical Pharmacology Medical Faculty of Novi Sad, Novi Sad, Serbia<\/em><\/p>\n

\u00a0<\/em><\/p>\n<\/td>\n<\/tr>\n

\n

09:40 – 10:10<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Preclinical studies in CNS drug development<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Prof. Dr. Bernadeta Sewczyk<\/u><\/em><\/strong>, Head of the Department of Neurobiology, May Institute of Pharmacology, Polish Academy of Sciences, Krak\u00f3w, Poland<\/em><\/p>\n

\u00a0<\/em><\/p>\n<\/td>\n<\/tr>\n

\n

10:10 – 10:40<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Chemobrain and cognitive impairment due to oncotherapy. <\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Prof. Dr. Joanna Wiero\u0144ska<\/u><\/em><\/strong>, Head of the Laboratory of Neurobiology of Psychiatric Disorders, Department of Neurobiology, May Institute of Pharmacology, Polish Academy of Sciences, Krak\u00f3w, Poland <\/em><\/p>\n

\u00a0<\/em><\/p>\n<\/td>\n<\/tr>\n

\n

10:40 – 11:10<\/strong><\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Coffee Break<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

11:10 – 11:40<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Myth and Facts of tumormarkers and other laboratory biomarkers in oncology<\/strong><\/p>\n

 <\/p>\n

Prof. Dr. Ondrej Topolcan<\/u><\/em><\/strong>,<\/u><\/em> Head of Central Laboratory for Immunoanalysis, Head of the Department of Immunochemistry and Biobank at the University Hospital Pilsen, Deputy Director of the Biobank at the Faculty of Medicine, Charles University in Prague, Deputy Director for Science and Research at the University Hospital Pilsen, Faculty of Medicine in Pilzen, Charles University, Czech Republic<\/em><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

11:40 \u2013 12:10<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Onco-interventions – Expanding opportunities in the everyday clinical oncology practice<\/strong><\/p>\n


\nDr. D\u00e9nes Bal\u00e1zs <\/u><\/em><\/strong>Horv\u00e1thy<\/strong><\/span>, Senior<\/em> Lecturer, Department of Interventional Radiology,
\nSemmelweis University, Budapest, Hungary <\/em><\/p>\n<\/td>\n<\/tr>\n

\n

12:10 \u2013 12:20<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Changing Landscape in Oncology Treatment and Oncotherapy<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Dr. M\u00e1t\u00e9 \u00c1d\u00e1m Bal\u00e1zs<\/u><\/em><\/strong>, secretary, Pharmacovigilance and Patient Safety Research Group, Oncology Unit, Department of Internal Medicine and Oncology, Semmelweis University, <\/em>Budapest, Hungary<\/em><\/p>\n

\u00a0<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

12:55 \u2013 13:05<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Youth Researcher Student Award Ceremony<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

13:05 \u2013 13:15<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

A Conclusive Case Series: Cardiotoxicity mediated by HER2-targeted therapy represents real threats in the metastatic setting<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Devarajulu Mariyappan<\/u><\/em><\/strong>, student research associate, <\/em>Pharmacovigilance and Patient Safety Research Group, Oncology Unit, Department of Internal Medicine and Oncology, Semmelweis University, <\/em>Budapest<\/em><\/p>\n

\u00a0<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

13:15 – 14:15<\/strong><\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Lunch Break<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

14:15 – 14:45<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Nutritional therapy – As an essential part of onco-rehabilitation <\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Dr. Erzs\u00e9bet P\u00e1lfi<\/u><\/em><\/strong>, associate professor, Department of Dietetics and Nutrition Sciences, Faculty of Health Sciences, Semmelweis University, <\/em>Budapest, Hungary<\/em><\/p>\n

\u00a0<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

14:45 – 15:15<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Perspectives for PARP1 inhibitors for the treatment of glioma and breast cancer<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Dr. habil. Agnieszka Zagorska <\/u><\/em><\/strong>assistant professor, Department of Medicinal Chemistry, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University, Krakow, Poland<\/em><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

15:15 – 15:45<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Coffe Break<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

15:45 – 16:15<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Is there a role for nurses in pharmacovigilance \u2013 what can pharmacovigilance nurse mean?<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Dallakoti Sraddha<\/u><\/em><\/strong>,\u2013 Semmelweis University, Department of Internal Medicine and Oncology, Oncology Unit, Pharmacovigilance and Patient Safety Research Group<\/em>\u00a0<\/strong><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

16:15 \u2013 16:45<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Drug-Induced Speech Disorders – The Speech-Language Pathologist as a Potential Source of Medication Safety Insight<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

\u00c1d\u00e1m Attila Sz\u00fccs<\/u><\/em><\/strong>, <\/em>Center for Geriatric Care and Nursing Science, Semmelweis University, Budapest, Hungary<\/em><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

16:45 \u2013 17:15<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Intersections of Oncology and Geriatrics \u2013 Geriatric Rehabilitation and Oncology<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Abu Baker<\/u><\/em><\/strong>, <\/em>Center for Geriatric Care and Nursing Science, Semmelweis University, Budapest, Hungary<\/em><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

17:15 \u2013 17:30<\/p>\n<\/td>\n

\n

\u00a0<\/strong><\/p>\n

Closing Remarks<\/strong><\/p>\n

\u00a0<\/em><\/p>\n

Dr. M\u00e1t\u00e9 \u00c1d\u00e1m Bal\u00e1zs<\/u><\/em><\/strong>, secretary, Pharmacovigilance and Patient Safety Research Group, Oncology Unit, Department of Internal Medicine and Oncology, Semmelweis University, <\/em>Budapest, Hungary<\/em><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

*The organizers reserve the right to change the program.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

INVITATION \u00a0 \u00a0 We kindly invite you to the scientific event organized by the Pharmacovigilance and Patient Safety Research Group, Department of Internal Medicine and Oncology, Oncology Unit, Semmelweis University and the Central and Eastern European Academy of Oncology: \u00a0 1st Winter School of Pharmacovigilance and Patient Safety Research Group \u00a0 Inter- and Multidisciplinary Chapters …<\/p>\n","protected":false},"author":102500,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3526","post","type-post","status-publish","format-standard","hentry","category-hirek"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/posts\/3526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/users\/102500"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/comments?post=3526"}],"version-history":[{"count":10,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/posts\/3526\/revisions"}],"predecessor-version":[{"id":3548,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/posts\/3526\/revisions\/3548"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/media?parent=3526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/categories?post=3526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/onkologiai-kozpont\/wp-json\/wp\/v2\/tags?post=3526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}